Sphingosine-1-phosphate receptor inhibition prevents denervation-induced dendritic atrophy
© Willems et al. 2016
Received: 10 February 2016
Accepted: 16 March 2016
Published: 31 March 2016
A hallmark of several major neurological diseases is neuronal cell death. In addition to this primary pathology, secondary injury is seen in connected brain regions in which neurons not directly affected by the disease are denervated. These transneuronal effects on the network contribute considerably to the clinical symptoms. Since denervated neurons are viable, they are attractive targets for intervention. Therefore, we studied the role of Sphingosine-1-phosphate (S1P)-receptor signaling, the target of Fingolimod (FTY720), in denervation-induced dendritic atrophy. The entorhinal denervation in vitro model was used to assess dendritic changes of denervated mouse dentate granule cells. Live-cell microscopy of GFP-expressing granule cells in organotypic entorhino-hippocampal slice cultures was employed to follow individual dendritic segments for up to 6 weeks after deafferentation. A set of slice cultures was treated with FTY720 or the S1P-receptor (S1PR) antagonist VPC23019. Lesion-induced changes in S1P (mass spectrometry) and S1PR-mRNA levels (laser microdissection and qPCR) were determined. Denervation caused profound changes in dendritic stability. Dendritic elongation and retraction events were markedly increased, resulting in a net reduction of total dendritic length (TDL) during the first 2 weeks after denervation, followed by a gradual recovery in TDL. These changes were accompanied by an increase in S1P and S1PR1- and S1PR3-mRNA levels, and were not observed in slice cultures treated with FTY720 or VPC23019. We conclude that inhibition of S1PR signaling prevents dendritic destabilization and denervation-induced dendrite loss. These results suggest a novel neuroprotective effect for pharmaceuticals targeting neural S1PR pathways.
During the past years considerable effort has been made to better understand the pathophysiological mechanisms underlying neuronal cell loss or alterations in synaptic transmission in neurological and psychiatric diseases [1, 2]. However, far less attention has been dedicated to secondary injuries, e.g., neuronal denervation and atrophy, which invariably occur after traumatic, ischemic, haemorrhagic, neurodegenerative or neuroinflammatory brain damage in areas connected to the primary lesion site [3, 4]. These transneuronal effects on the neuronal network contribute considerably to the clinical symptoms [5, 6]. Moreover, maladaptive structural and functional changes in deafferented, but otherwise healthy brain regions have been implicated in several lesion-related long-term complications such as pain, epilepsy or memory dysfunction .
The role of structural and functional disconnection is of particular interest in Multiple Sclerosis (MS), since some of the cognitive deficits and other symptoms seen in patients have been attributed to perturbations of network function [5, 6]. Current pharmacological treatment focuses on the primary mechanism of injury and aims at modulating the immune system in order to prevent axonal damage and cell loss [8–10]. Secondary changes, triggered by denervation-induced transneuronal alterations, have so far not been considered a target. Interestingly, recent experimental evidence suggests that several immune mediators and inflammatory signaling pathways influence neuronal plasticity [1, 11–13]. Among them are sphingosine-1-phosphate (S1P) and its signaling pathways [14, 15], which are the targets of the oral immune-modulating drug Fingolimod (FTY720), now widely used in MS-therapy [16–18]. Therefore, we hypothesized that S1P-receptor (S1PR) modulation interferes with secondary brain injury by acting directly on neural tissue.
Materials and methods
Preparation and maintenance of slice cultures
Experimental procedures were performed in agreement with the German law on the use of laboratory animals and approved by the animal welfare officer of Goethe-University (Faculty of Medicine). Entorhino-hippocampal slice cultures were prepared at postnatal day 4–5 from Thy1-GFP mice  of either sex as previously described [22, 24]. In these cultures a subset of neurons expresses GFP, which allows for the visualization of neurons in living tissue (Fig. 1). Cultivation medium contained 50 % MEM (v/v), 25 % basal medium eagle (v/v), 25 % heat-inactivated normal horse serum (v/v), 25 mM HEPES buffer solution, 0.15 % bicarbonate (w/v), 0.65 % glucose (w/v), 0.1 mg/ml streptomycin, 100 U/ml penicillin, and 2 mM glutamax. pH was adjusted to 7.3 and medium was replaced three times per week. All slice cultures were allowed to mature for 18–20 d in a humidified atmosphere with 5 % CO2 at 35 °C before they were used for experiments.
Slice cultures show an organotypic morphology . In slice cultures of entorhinal cortex and hippocampus the entorhino-dentate fiber tract, i.e., perforant pathway is present (Fig. 1a, b) and terminates on dentate granule cells in an organotypic pattern. In mature (18–20 days in vitro) mouse slice cultures this innervation pattern is stable and can be studied for several weeks in vitro using time-lapse imaging [21, 22]. Using a sterile scalpel blade we transected the entorhino-dentate fiber tract under visual control by cutting through the culture from the rhinal fissure to the hippocampal fissure. To ensure complete and permanent separation of the entorhinal cortex from the hippocampus, the entorhinal cortex was subsequently removed in every denervation experiment and only the de-entorhinated hippocampus remained in the dish (Fig. 1b). Of note, in previous studies we have shown that this procedure does not directly damage the target neurons in the dentate gyrus. Rather, this mechanical transection results in a highly standardized and reproducible loss of entorhinal axons in the outer molecular layer (see inset in Fig. 1b). The distal dendrites of dentate granule cells (Fig. 1c, d) are heavily denervated and lose a considerable portion of their synaptic inputs (~85–90 % of synapses in vivo ).
For anterograde tracing of the entorhino-hippocampal pathway a biotinylated and rhodamine-conjugated dextranamine (“mini-rubi”, Molecular Probes, Life Technologies, USA) crystal was placed on the entorhinal cortex [26, 27]. 3–4 days later cultures were fixed in a solution of 4 % (w/v) paraformaldehyde and 4 % (w/v) sucrose in phosphate buffered saline (PBS) for 1 h, then washed thoroughly and coverslipped with fluorescent mounting medium (DAKO, Germany). For nuclear staining cultures were incubated with Topro-3-iodide (1:5000 in PBS for 10 min; Invitrogen, USA). Traced entorhino-hippocampal fibers were visualized using a Nikon Eclipse C1si laser-scanning microscope equipped with a 40× oil-immersion (NA 1.3, Nikon) and 60× oil-immersion (NA 1.4, Nikon) objective lens (Fig. 1b).
Long-term time-lapse imaging of dentate granule cells in slice cultures
Denervated and non-denervated slice cultures were treated with FTY720 (1 μM; Selleck Chemicals, 162359560), VPC23019 (; 1 μM; VPC23019, R- Phosphoric acid mono-ester; Tocris 4195) or S1P (1 μM, Biotrend, BS0186) by applying the respective drug (or vehicle-only) after the first imaging session (and immediately after the lesion; c.f., Fig. 2a) to the incubation medium and to the imaging solution. Drug- or vehicle-containing incubation medium was replaced three times per week. We did not observe any evidence for toxicity (blebbing, dendritic atrophy/retraction) in our time lapse imaging experiments of non-denervated cultures treated with either FTY720 or VPC23019. In these imaging experiments the control cells were stable and not a single imaged cell was lost under these conditions. Thus, we feel confident that our observations are not confounded by a toxic effect of these drugs on neural tissue.
Reconstruction of the dendritic tree
Laser capture microdissection (LMD) of re-sliced cultures
Slice cultures were washed with phosphate buffered saline (PBS; 0.1 M, pH 7.4), shock frozen at −80 °C in tissue freezing medium (Leica Microsystems, Germany), re-sliced into 10 μm thick slices on a cryostat (Leica CM 3050 S) and mounted on PET foil metal frames (Leica, Germany) as described previously [20, 26]. Re-sliced cultures were fixed in ice-cold acetone for 1 min and incubated with 0.1 % toluidine blue (Merck, Germany) at room temperature for 1 min, before rinsing in ultrapure water (DNase/RNase free, Invitrogen, USA) and 70 % ethanol. PET foil metal frames were mounted on a Leica DM 6000B LMD system (Leica Microsystems, Germany) with the section facing downward. After adjusting intensity, aperture, and cutting velocity, the pulsed ultraviolet laser beam was carefully directed along the borders of the respective hippocampal layers of interest using a 20x objective lens (Leica Laser Microdissection, Software Version 220.127.116.1153). Tissue from the outer and inner molecular layer (OML, IML) and the granule cell layer (GCL) of the suprapyramidal blade of the dentate gyrus were collected (Fig. 4a). Microdissected tissue was transferred by gravity into microcentrifuge tube caps placed underneath the sections, filled with 50 μl guanidine isothiocyanate (GITC)-containing buffer (RLT Buffer, RNeasy Mini Kit, Qiagen) with 1 % ß-mercaptoethanol (AppliChem GmbH, Germany). Successful tissue collection was verified by visually inspecting the content of the tube caps. All samples were frozen and stored at −80 °C.
Isolating RNA and qPCR
RNA was isolated using the RNeasy® MicroPlus Kit (Qiagen, Germany). RNA integrity number (RIN; Fig. 4b) was determined using the Agilent 2100 Bioanalyzer system and Agilent RNA 6000 Pico Kit (Agilent Technologies, Germany). Purified RNA was transcribed into cDNA with the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, USA). All kits and assays were used according to the manufacturer’s instructions. The cDNA was amplified using the TaqMan®PreAmp Master Mix Kit (Applied Biosystems, USA) using 5 μl PreAmp Master Mix (Applied Biosystems, USA) + 2.5 μl cDNA + 2.5 μl Assay Mix [TaqMan Gene Expression™-Assay; GAPDH: 4352932E; sphingosine-1-receptor 1 (S1PR1) Mm00514644_m1eas; sphingosine-1-receptor 3 (S1PR1R3) Mm02620181_s1 from Applied Biosystems, USA] with a standard amplification protocol (14 cycles: 95 °C for 15 s; 60 °C for 4 min). Amplified cDNAs were diluted 1:20 in ultrapure water and subjected to qPCR (Fig. 4c; StepOnePlus, Applied Biosystems, USA) using a standard amplification program (1 cycle of 50 °C for 2 min, 1 cycle of 95 °C for 10 min, 40 cycles of 95 °C for 15 s and 60 °C for 60 s; cut off at 30 cycles; average CT-value was: 20.0 ± 0.9 cycles).
Quantification and statistics
To minimize error, segments of cultures with entorhinal lesions were compared to segments of age- and time-matched cultures without lesions, which were imaged the same number of times using the same imaging protocol. Every analysis was performed with the person analyzing dendritic morphologies blind to experimental condition.
qPCR-data were analyzed as described by Pfaffl . GAPDH served as reference gene in this analysis. The qPCR assay efficiency was calculated with the StepOnePlus software (Applied Biosystems, USA) based on a dilution series of 5 samples for each assay. Data of non-denervated control cultures (age- and time-matched to denervated cultures) were pooled.
Statistical comparisons were made using non-parametric Wilcoxon-Mann–Whitney test or the Kruskal-Wallis-test followed by Dunn’s post-hoc-test, which takes multiple comparisons into consideration. P-values of less than 0.05 were considered significant. All values represent means ± standard error of the mean (sem). In the figures * denotes p <0.05, ** p <0.01 and *** p <0.001; not significant differences are indicated with ‘ns’.
Confocal image stacks were exported as 2D-projections from the Zeiss LSM image browser and stored as TIF files. Figures were prepared using Photoshop graphics software (Adobe, USA). Image brightness and contrast were adjusted.
Denervation induces a loss in total dendritic length
Time-lapse microscopy of organotypic slice cultures prepared from Thy1-GFP mice  was used to determine the dynamics of denervation-induced dendritic remodeling. Single denervated GFP-expressing granule cells and single age- and time-matched non-denervated GFP-expressing granule cells were repeatedly imaged over time (Fig. 2a, b). Changes in total dendritic length (TDL) were determined in the two groups (Fig. 2c). Entorhinal denervation in vitro caused a decrease in TDL during the first 2 weeks after lesion, which was followed by a gradual recovery in TDL at later time points (>14 days post lesion, dpl). Control cultures did not show any significant change in TDL over time. These data are consistent with previous studies demonstrating reduction in dendritic length followed by partial recovery in TDL upon entorhinal denervation in vivo [31, 32]. They confirmed the validity of our in vitro model to study the cellular and molecular mechanisms of denervation-induced dendritic remodeling.
Denervation affects the dynamics of dendrites and causes loss of dendritic segments
In order to assess the dynamics of the lesion-induced dendritic reorganization process, we compared neuronal reconstructions of granule cells at consecutive time points (Fig. 2d). This made it possible to assess elongation and retraction of individual dendritic segments separately. In control cultures changes of distal dendritic segments were detected under baseline conditions (within a range of ± 30–40 μm between imaging sessions). Approximately 5–7 % of the TDL was found to be dynamically remodeled between consecutive points in time. These alterations did not directly affect TDL since elongation and retraction events canceled out. Dendritic arborization was also unchanged, since neither loss of existing nor formation of new dendritic segments was seen. We concluded that under control conditions dendritic dynamics are in a homeostatic steady-state and TDL remains constant.
In the denervated group time-lapse imaging revealed profound changes in dendritic dynamics and arborization (Fig. 2d). In some cases individual segments disappeared without reappearing during the recovery phase (see arrow in Fig. 2b). Formation of new dendrites was not observed. Much to our surprise dendritic retraction and elongation were elevated during the early and the late phase after denervation. These results suggested that atrophic and compensatory dendritic changes occur in parallel and are both detectable even at a late stage after the lesion, i.e., when TDL recovers. During the early phase (0–14 dpl) retraction exceeded elongation, while at a later stage (>14 dpl) elongation surpassed retraction (Fig. 2d, e). These changes in dendritic dynamics were sufficient to explain the time course of granule cell TDL following entorhinal denervation in vitro.
Inhibition of S1P-receptor signaling maintains granule cell dendrites after denervation
To test for the role of FTY720 and S1PR signaling in denervation-induced dendritic remodeling, we repeated deafferentation experiments in a new set of cultures which were treated with FTY720 (1 μM) immediately after the lesion. Non-denervated FTY720-treated cultures served as controls (Fig. 3a-d). These cultures were imaged in the same way as the denervated cultures. Strikingly, FTY720 treatment prevented the denervation-induced loss in TDL. Only at 4 dpl a significant reduction in TDL was briefly observed. Analysis of dendritic elongation and retraction revealed that FTY720 acts by stabilizing granule cell dendrites, i.e., by preventing the denervation-induced increase in dendritic remodeling. Of note, the dendritic arbor was also maintained since dendritic segments were neither lost nor newly formed after deafferentation.
To confirm and extend these results, another set of control and denervated cultures was treated with VPC23019 (1 μM), which is a competitive S1PR1/3 inhibitor (Fig. 3e-h ). In these experiments no changes in TDL were observed over time, both in VPC23019-treated denervated and non-denervated cultures. Very similar to FTY720, VPC23019 also prevented the denervation-induced destabilization of dendrites. Statistical comparison of these results with data obtained in cultures that were not pharmacologically treated (c.f., Fig. 2) confirmed that neither FTY720 nor VPC23019 affect TDL and dendritic dynamics under non-denervated control conditions, while preventing the denervation-induced dendritic changes (Kruskal-Wallis-test followed by Dunn’s post-hoc-test).
Taken together, these findings suggested that inhibition of S1PR signaling prevents denervation-induced dendritic atrophy by stabilizing the dendrites of partially deafferented neurons. Since the peripheral immune system is absent in slice culture preparations, these results indicated that FTY720 could act directly on neural tissue [33–35].
Upregulation of S1P-receptor 1 and 3 mRNA in the denervated outer molecular layer following entorhinal denervation in vitro
Because both FTY720 and VPC23019 act via S1PRs, we wondered whether these receptors are expressed and regulated in the dentate gyrus following denervation (Fig. 4). We focused on S1PR1 and S1PR3 in these experiments, since earlier work indicated that FTY720 acts predominantly via these receptors [16, 36, 37]. Laser capture microdissection (LMD) was used to harvest tissue from the denervated OML, the non-denervated IML and the GCL in control and denervated cultures at 2, 7 and 14 dpl (Fig. 4a). RNA integrity numbers (RIN) of harvested tissue was excellent (Fig. 4b). Changes in mRNA levels were determined in laser microdissected material by qPCR. A significant increase in S1PR1- and S1PR3-mRNA levels was detected in the denervated OML (Fig. 4c), while no significant changes were observed in the IML and GCL (data not shown). S1PR3-mRNA was increased at 2 dpl, while S1PR1-mRNA showed a later increase at 7 dpl (Fig. 4c).
S1P levels are upregulated after denervation
We next tested whether entorhinal denervation leads to an increase in S1P levels in hippocampal tissue (Fig. 4d). Indeed, mass spectrometry disclosed a gradual increase of S1P levels in denervated cultures, reaching the level of significance by 14 dpl in comparison to non-denervated controls. Together with our LMD/qPCR data these results demonstrated an upregulation of both the ligand as well as the receptors in the dentate gyrus following denervation.
S1P-treatment is not sufficient to induce dendritic atrophy in control cultures
Neurological diseases associated with neuronal cell death show primary damage at the lesion site and widespread secondary damage in connected brain regions. Secondary damage, mainly caused by the loss of innervating axons originating from neurons at the primary lesion site, severely disrupts otherwise unaffected and healthy brain areas and perturbs network function. Of note, secondary damage is largely independent of the underlying cause of the disease and almost invariably accompanied by neuronal atrophy [6, 38]. Even though secondary brain damage has now been recognized as a major factor contributing to neurological diseases, it has not been targeted for therapeutic intervention. We regard it as one of the major findings of our study that a clinically used immune-modulating drug, i.e., FTY720, is able to act directly on neural tissue and prevents transneuronal denervation-induced dendrite loss. This effect is mediated by inhibition of neural S1P signaling. Considering that an increase in S1P-levels and S1P-receptor mRNAs is also detected after deafferentation, we propose that clinically used S1PR-modulators may act directly on denervated neuronal networks irrespective of the underlying cause of the disease.
Denervation affects dendritic stability and results in the rarefication of the dendritic arbor
Transneuronal degeneration of neurons after denervation has been well-described by several authors in different species and brain regions using in vivo lesions and perfusion-fixed tissue [3, 4]. We recently revisited this phenomenon and assessed changes in granule cell dendrites following entorhinal denervation in Thy1-GFP mice in vivo . Using the same approach as in these earlier studies, we reported a protracted loss of dendrites, i.e., the rarefication of the dendritic arbor, which was followed by partial recovery of TDL at a later stage after denervation. Of note, in all of these studies - including our own - these changes were interpreted as the result of an initial degenerative and atrophic process followed by a partial regrowth of dendrites at later time points.
By using organotypic slice cultures, in vitro lesions and time-lapse imaging, we developed an in vitro system, which can be used to image the same denervated neuron over time and which makes it possible to study transneuronal changes dynamically [21, 22]. This approach revealed a constant remodeling of distal granule cell dendrites, similar to what has been reported for pyramidal cell dendrites in vivo using cranial windows . In control cultures the retraction and elongation of dendritic segments appeared to be in a well-tuned, i.e., homeostatic, equilibrium. Thus, TDL remained stable over long observation periods. As predicted, denervation destabilized granule cell dendrites and increased the retraction of dendrites. In some cases entire segments were lost, which died back to the branch point and disappeared. However, increased dendritic retraction was also observed during the recovery phase of TDL (>14 days post lesion). Moreover and quite unexpectedly, dendritic elongation was also increased immediately after the lesion. During the phase of TDL loss (first 2 weeks), retraction exceeded reactive elongation, whereas during the phase of TDL recovery (weeks 3–6) elongation exceeded retraction. In sum, denervation does not result in the expected sequential change of dendrite loss followed by a period of dendrite regrowth. Rather, denervation causes a profound and long-lasting destabilization of granule cell dendrites, which involves increases in both elongation and retraction. Changes in TDL which accompany denervation are the result of an altered balance between these two phenomena.
FTY720 treatment results in the stabilization of denervated dendrites
Based on reports that S1P-receptor signaling is involved in neuronal plasticity (e.g., [34, 40, 41]), regulation of neurite remodeling (e.g., [40, 42]), and neuroprotection (e.g., [33, 43, 44]) and also because of the relevance of FTY720 in the treatment of MS, we wondered whether FTY720 could have an influence on denervation-induced dendritic changes. Indeed, FTY720 prevented the denervation-induced reduction in TDL. Furthermore, dynamic imaging revealed that FTY720 stabilizes denervated dendrites and thus prevents the denervation-induced change in the balance of dendritic retraction and elongation. This "neuro-stabilization" seems to be a direct effect of FTY720 on neural tissue, since the peripheral immune system, which is regarded as the main target of FTY720, is missing in organotypic slice culture preparations. To control for off-target effects of FTY720 (and its agonist–antagonist properties; [16–18]), we repeated these experiments with the S1PR1/3-inhibitor VPC23019 and obtained very similar results. Hence, together with our LMD-qPCR and mass spectrometry data - which disclose an increase in both the ligand and the receptor - we are confident to conclude that S1P signaling pathways are involved in mediating denervation-induced plasticity.
Which cell biological processes could be relevant? At present little is known about the cellular and molecular mechanisms regulating denervation-induced dendritic retraction and elongation in adult neurons. Changes in neuronal cytoskeleton, e.g., changes in microtubule dynamics, are necessary for the formation of dendritic arbors during development and similar mechanisms are likely to play a role. Whether these cellular changes are brought about by external signals deriving from degenerating axon terminals or activated glial cells or are a response of the neuron to changes in its afferent activity is currently unclear. Likewise, glial cells [45–47], neurotrophic factors [33, 42], histone acetylation , and other aspects of injury-induced neuroinflammation [6, 38] could play a role. Notably, recent work has suggested that FTY720 may prevent p75NTR up-regulation and astrocyte-mediated inflammation . Considering that these signaling pathways are known to affect dendritic morphology [50, 51] and our own recent work on TNF in denervation-induced plasticity [26, 52], it is possible that FTY720 could act through p75NTR in our experimental setting. Regardless of these considerations, which show that we urgently need a more thorough molecular understanding of disease-related neuronal reorganization processes, our data clearly show that FTY720 prevents structural changes of denervated granule cells and stabilizes their dendritic arbor in the absence of their specific input.
The S1P signaling pathway is permissive for dendritic remodeling
Since FTY720 prevented denervation-induced dendritic changes of granule cells, we hypothesized that S1PRsignaling is involved in this process. Therefore, we investigated changes in S1P after denervation and found, by using mass spectrometry, that S1P is present in our preparations and that levels of S1P increase following entorhinal denervation. Since VPC23019 had similar effects as FTY720, we focused on S1PR1 and S1PR3 as the most likely S1P-receptors to be involved. Indeed, mRNAs of both receptors were found to be present and upregulated in the denervated outer molecular layer of the dentate gyrus . Together, these data strongly implicate S1P and S1P signaling via S1PR1 and S1PR3 in denervation-induced dendritic remodeling.
Interestingly, neither addition of S1P (at ~103x higher concentration compared to the measured endogenous S1P-levels in denervated cultures) nor the addition of either FTY720 or VPC23019 to the culture medium had effects on granule cell dendrites and their dynamics in non-denervated control cultures. These experiments demonstrate that S1P signaling is neither sufficient nor instructive for the induction of dendritic changes, nor is it necessary for the maintenance of non-denervated dendrites (c.f., ). Postlesional changes of S1PR or their signaling pathways might be required for granule cells to become sensitive to S1P. Under such conditions S1P could influence the dynamics of dendrites and could regulate dendritic remodeling. From a therapeutic point-of-view such an “effect-dependence” on denervation conditions is of considerable benefit, since treatment with FTY720 will not alter the dynamics of dendrites of non-denervated neurons in other brain areas.
FTY720 is an orally active drug used in clinical medicine for the treatment of MS [8–10]. It is believed to act primarily on circulating lymphocytes and lymphnodes, i.e., immune cells outside the CNS  (for review see [16, 56]). Consistent with work of other groups [33–35] our data disclose that FTY720 can also interfere with S1P signaling in neural tissue, and can prevent a loss of dendrites upon deafferentation. Although the functional consequences of dendritic atrophy and dendritic reorganization on a denervated neuronal network are still unclear and some authors have even suggested homeostatic functions , it is attractive to speculate that the ability of FTY720 to stabilize denervated dendrites is one of the reasons why this drug has a beneficial effect for MS patients. For example, during periods of neuroinflammation FTY720 could maintain partially denervated dendrites until surviving or recovering axons reinnervate the dendritic tree. Thus, FTY720 could prevent a loss of dendritic complexity as seen in long-term denervated neurons [31, 32], which may limit a neuron’s ability to process and integrate information from different inputs.
Entorhinal denervation causes profound and long-lasting destabilization of granule cell dendrites. Changes in dendritic length are the result of an altered balance between elongation and retraction of dendrites: During an early phase after denervation dendritic retraction exceeds elongation, followed by a later stage during which elongation surpasses retraction. Inhibition of S1PR signaling prevents dendritic destabilization and denervation-induced dendrite loss. Whether or not FTY720 or other drugs acting via S1PR pathways could minimize secondary damage to neurons in MS or in other neurological diseases now needs to be investigated using appropriate in vivo models.
We thank Charlotte Nolte-Uhl for her skilful assistance in tissue culturing and Dr. Denise Becker for help in data analysis.
This work was supported by LiFF (Lipid Signaling Forschungszentrum Frankfurt; LOEWE; KS, TD and AV) and Deutsche Forschungsgemeinschaft (FOR1332 and CRC 1080; TD and AV).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Shie FS, Chen YH, Chen CH, Ho IK. Neuroimmune pharmacology of neurodegenerative and mental diseases. J Neuroimmune Pharmacol. 2011;6:28–40.View ArticlePubMedGoogle Scholar
- Viviani B, Gardoni F, Marinovich M. Cytokines and neuronal ion channels in health and disease. Int Rev Neurobiol. 2007;82:247–63.View ArticlePubMedGoogle Scholar
- Deller T, Frotscher M. Lesion-induced plasticity of central neurons: sprouting of single fibres in the rat hippocampus after unilateral entorhinal cortex lesion. Prog Neurobiol. 1997;53:687–727.View ArticlePubMedGoogle Scholar
- Perederiy JV, Westbrook GL. Structural plasticity in the dentate gyrus- revisiting a classic injury model. Front Neural Circuits. 2013;7:17.View ArticlePubMedPubMed CentralGoogle Scholar
- Calabrese P, Penner IK. Cognitive dysfunctions in multiple sclerosis--a “multiple disconnection syndrome”? J Neurol. 2007;2007(254 Suppl 2):II18–21.Google Scholar
- Siffrin V, Vogt J, Radbruch H, Nitsch R, Zipp F. Multiple sclerosis - candidate mechanisms underlying CNS atrophy. Trends Neurosci. 2010;33:202–10.View ArticlePubMedGoogle Scholar
- Hughes PE, Alexi T, Walton M, et al. Activity and injury-dependent expression of inducible transcription factors, growth factors and apoptosis-related genes within the central nervous system. Prog Neurobiol. 1999;57:421–50.View ArticlePubMedGoogle Scholar
- Tanasescu R, Ionete C, Chou IJ, Constantinescu CS. Advances in the treatment of relapsing - Remitting multiple sclerosis. Biomed J. 2014;37:41–9.View ArticlePubMedGoogle Scholar
- Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New Engl J Med. 2010;362:402–15.View ArticlePubMedGoogle Scholar
- Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New Engl J Med. 2010;362:387–401.View ArticlePubMedGoogle Scholar
- Camacho-Arroyo I, Lopez-Griego L, Morales-Montor J. The role of cytokines in the regulation of neurotransmission. Neuroimmunomodulation. 2009;16:1–12.View ArticlePubMedGoogle Scholar
- Pribiag H, Stellwagen D. Neuroimmune regulation of homeostatic synaptic plasticity. Neuropharmacology. 2014;78:13–22.View ArticlePubMedGoogle Scholar
- Santello M, Volterra A. TNFalpha in synaptic function: switching gears. Trends Neurosci. 2012;35:638–47.View ArticlePubMedGoogle Scholar
- Huwiler A, Pfeilschifter J. New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets. Biochem Pharmacol. 2008;75:1893–900.View ArticlePubMedGoogle Scholar
- Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9:139–50.View ArticlePubMedGoogle Scholar
- Brinkmann V. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol. 2009;158:1173–82.View ArticlePubMedPubMed CentralGoogle Scholar
- Ingwersen J, Aktas O, Kuery P, Kieseier B, Boyko A, Hartung HP. Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy. Clin Immunol. 2012;142:15–24.View ArticlePubMedGoogle Scholar
- Brunkhorst R, Vutukuri R, Pfeilschifter W. Fingolimod for the treatment of neurological diseases-state of play and future perspectives. Front Cell Neurosci. 2014;8:283.View ArticlePubMedPubMed CentralGoogle Scholar
- Vlachos A, Becker D, Jedlicka P, Winkels R, Roeper J, Deller T. Entorhinal denervation induces homeostatic synaptic scaling of excitatory postsynapses of dentate granule cells in mouse organotypic slice cultures. PLoS One. 2012;7:e32883.View ArticlePubMedPubMed CentralGoogle Scholar
- Vlachos A, Ikenberg B, Lenz M, et al. Synaptopodin regulates denervation-induced homeostatic synaptic plasticity. Proc Natl Acad Sci U S A. 2013;110:8242–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Vlachos A, Helias M, Becker D, Diesmann M, Deller T. NMDA-receptor inhibition increases spine stability of denervated mouse dentate granule cells and accelerates spine density recovery following entorhinal denervation in vitro. Neurobiol Dis. 2013;59:267–76.View ArticlePubMedGoogle Scholar
- Vlachos A, Bas Orth C, Schneider G, Deller T. Time-lapse imaging of granule cells in mouse entorhino-hippocampal slice cultures reveals changes in spine stability after entorhinal denervation. J Comp Neurol. 2012;520:1891–902.View ArticlePubMedGoogle Scholar
- Feng G, Mellor RH, Bernstein M, et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron. 2000;28:41–51.View ArticlePubMedGoogle Scholar
- Del Turco D, Deller T. Organotypic entorhino-hippocampal slice cultures--a tool to study the molecular and cellular regulation of axonal regeneration and collateral sprouting in vitro. Methods Mol Biol. 2007;399:55–66.View ArticlePubMedGoogle Scholar
- Hoff SF, Scheff SW, Benardo LS. Cotman CW (1982) Lesion-induced synaptogenesis in the dentate gyrus of aged rats: I. Loss and reacquisition of normal synaptic density. J Comp Neurol. 1982;205:246–52.View ArticlePubMedGoogle Scholar
- Becker D, Zahn N, Deller T, Vlachos A. Tumor necrosis factor alpha maintains denervation-induced homeostatic synaptic plasticity of mouse dentate granule cells. Front Cell Neurosci. 2013;7:257.View ArticlePubMedPubMed CentralGoogle Scholar
- Jungblut D, Vlachos A, Schuldt G, Zahn N, Deller T, Wittum G. SpineLab: tool for three-dimensional reconstruction of neuronal cell morphology. J Biomed Opt. 2012;17:076007.View ArticlePubMedGoogle Scholar
- Davis MD, Clemens JJ, Macdonald TL, Lynch KR. Sphingosine 1-phosphate analogs as receptor antagonists. J Biol Chem. 2005;280:9833–41.View ArticlePubMedGoogle Scholar
- Grammatikos G, Muhle C, Ferreiros N, et al. Serum acid sphingomyelinase is upregulated in chronic hepatitis C infection and non alcoholic fatty liver disease. Biochem Biophys Acta. 2014;1841:1012–20.PubMedGoogle Scholar
- Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.View ArticlePubMedPubMed CentralGoogle Scholar
- Caceres A, Steward O. Dendritic reorganization in the denervated dentate gyrus of the rat following entorhinal cortical lesions: A Golgi and electron microscopic analysis. J Comp Neurol. 1983;214:387–403.View ArticleGoogle Scholar
- Vuksic M, Del Turco D, Vlachos A, et al. Unilateral entorhinal denervation leads to long-lasting dendritic alterations of mouse hippocampal granule cells. Exp Neurol. 2011;230:176–85.View ArticlePubMedGoogle Scholar
- Deogracias R, Yazdani M, Dekkers MP, et al. Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proc Natl Acad Sci U S A. 2012;109:14230–5.View ArticlePubMedPubMed CentralGoogle Scholar
- Kanno T, Nishizaki T, Proia RL, et al. Regulation of synaptic strength by sphingosine 1-phosphate in the hippocampus. Neuroscience. 2010;171:973–80.View ArticlePubMedGoogle Scholar
- Zhang DD, Linke B, Suo J, et al. (2015) Antinociceptive effects of FTY720 during trauma-induced neuropathic pain are mediated by spinal S1P receptors. Biol Chem [epub ahead of print].Google Scholar
- Mullershausen F, Zecri F, Cetin C, Billich A, Guerini D, Seuwen K. Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol. 2009;5:428–34.View ArticlePubMedGoogle Scholar
- Graeler M, Goetzl EJ. Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells. FASEB J. 2002;16:1874–8.View ArticlePubMedGoogle Scholar
- Zindler E, Zipp F. Neuronal injury in chronic CNS inflammation. Best Pract Res Clin Anaesthesiol. 2010;24:551–62.View ArticlePubMedGoogle Scholar
- Matter C, Pribadi M, Liu X, Trachtenberg JT. Delta-catenin is required for the maintenance of neural structure and function in mature cortex in vivo. Neuron. 2009;64:320–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Kempf A, Tews B, Arzt ME, et al. The sphingolipid receptor S1PR2 is a receptor for Nogo-a repressing synaptic plasticity. PLoS Biol. 2014;12:e1001763.View ArticlePubMedPubMed CentralGoogle Scholar
- Maggio N, Itsekson Z, Ikenberg B, et al. The anticoagulant activated protein C (aPC) promotes metaplasticity in the hippocampus through an EPCR-PAR1-S1P1 receptors dependent mechanism. Hippocampus. 2014;24:1030–8.View ArticlePubMedGoogle Scholar
- Toman RE, Payne SG, Watterson KR, et al. Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension. J Cell Biol. 2004;166:381–92.View ArticlePubMedPubMed CentralGoogle Scholar
- Kraft P, Gob E, Schuhmann MK, et al. FTY720 ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct neuroprotection. Stroke. 2013;44:3202–10.View ArticlePubMedGoogle Scholar
- Wei Y, Yemisci M, Kim HH, et al. Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol. 2011;69:119–29.View ArticlePubMedPubMed CentralGoogle Scholar
- Noda H, Takeuchi H, Mizuno T, Suzumura A. Fingolimod phosphate promotes the neuroprotective effects of microglia. J Neuroimmunol. 2013;256:13–8.View ArticlePubMedGoogle Scholar
- Colombo E, Di Dario M, Capitolo E, et al. Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide. Ann Neurol. 2014;76:325–37.View ArticlePubMedGoogle Scholar
- Brunkhorst R, Kanaan N, Koch A, et al. FTY720 treatment in the convalescence period improves functional recovery and reduces reactive astrogliosis in photothrombotic stroke. PLoS One. 2013;8:e70124.View ArticlePubMedPubMed CentralGoogle Scholar
- Hait NC, Wise LE, Allegood JC, et al. Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory. Nat Neurosci. 2014;17:971–80.View ArticlePubMedPubMed CentralGoogle Scholar
- Miguez A, Miguez A, García-Díaz Barriga G, et al. Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington’s disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation. Hum Mol Genet. 2015;24:4958–70.View ArticlePubMedGoogle Scholar
- Nakayama AY, Harms MB, Luo L. Small GTPases Rac and Rho in the maintenance of dendritic spines and branches in hippocampal pyramidal neurons. J Neurosci. 2000;20:5329–38.PubMedGoogle Scholar
- Zagrebelsky M, Holz A, Dechant G, et al. The p75 neurotrophin receptor negatively modulates dendrite complexity and spine density in hippocampal neurons. Neurosci. 2005;25:9989–99.View ArticleGoogle Scholar
- Becker D, Deller T, Vlachos A. Tumor necrosis factor (TNF)-receptor 1 and 2 mediate homeostatic synaptic plasticity of denervated mouse dentate granule cells. Sci Rep. 2015;5:12726.View ArticlePubMedPubMed CentralGoogle Scholar
- Van Doorn R, Van Horssen J, Verzijl D, et al. Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. Glia. 2010;58:1465–76.PubMedGoogle Scholar
- Rossi S, Lo Giudice T, De Chiara V, et al. Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis. Br J Pharmacol. 2012;165:861–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Choi JW, Gardell SE, Herr DR, et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci U S A. 2011;108:751–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Groves A, Kihara Y, Chun J. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci. 2013;328:9–18.View ArticlePubMedPubMed CentralGoogle Scholar
- Platschek S, Cuntz H, Vuksic M, Deller T, Jedlicka P (2016) A general homeostatic principle following lesion induced dendritic remodeling. Acta Neuropathol Commun (accepted).Google Scholar